On World Kidney Day Centaur Pharmaceuticals & Kibow Biotech, USA, Announce a Strategic Alliance to Market Renadyl in India for Chronic Kidney Illness

  • Prevalence of Chronic Kidney Illness in India is 17.2% and rising (Singh AK, Farag YM, Mittal BV, et al. Epidemiology and risk factors of chronic kidney disease in India– results from the SEEK (Screening and Early Evaluation of Kidney Disease) study. BMC Nephrology)
  • Dialysis is a painful and expensive process with scarcely available resources.
  • This novel, US-patented, and clinically-tested product helps maintain healthy kidney functions.

Commenting on this strategic alliance, Dr. Natarajan Ranganathan, Ph.D. (Bio-organic Chemistry), inventor of the globally patented product, and the Founder and Managing Director of Kibow Biotech, said, “As my roots are from India, I am extremely happy that my company Kibow Biotech has collaborated with Centaur Pharmaceuticals. Now we can together offer the benefits of my 20 years of research to millions of Indian patients suffering from Chronic Kidney Illness and make their lives better. Kibow also has an interesting research pipeline which we hope to bring to India for the benefit of Indian patients.”

Speaking on this occasion, Mr. S. D. Sawant, Chairman and MD of Centaur Pharmaceuticals, said, “Kibow has a strong research infrastructure and expertise in modulating gut microbiome. Through this alliance, Centaur will leverage Kibow’s research expertise and its own strong manufacturing and marketing skills to offer hope in the form of Renadyl to patients in India suffering from Chronic Kidney Illness. We are happy to announce this alliance in the backdrop of World Kidney Day and World Women’s Day coming up on 8th March.